Inbred mice exhibit a spectrum of susceptibility to induction of experimental allergic encephalomyelitis (EAE). We have compared the immune responses of the susceptible SJL (H-29 and resistant B10.S (H-2 S) strains to determine factors other than the MHC background which control resistance/susceptibility to EAE. The resistance of the B10.S strain was found to be secondary to an antigen-specific defect in the generation of Thl cells that produce IFN% This defect in IFN~/ production could be restored by exposure of the myelin basic protein (MBP)-reactive T cells to IL-12 with the subsequent induction of the ability to transfer EAE to naive recipients. These findings have important implications for the therapeutic use oflL-12 and IL-12 antagonists and may explain the association between relapses/exacerbation ofautoimmune disease and infectious diseases.
Summary
Inbred mice exhibit a spectrum of susceptibility to induction of experimental allergic encephalomyelitis (EAE). We have compared the immune responses of the susceptible SJL (H-29 and resistant B10.S (H-2 S) strains to determine factors other than the MHC background which control resistance/susceptibility to EAE. The resistance of the B10.S strain was found to be secondary to an antigen-specific defect in the generation of Thl cells that produce IFN% This defect in IFN~/ production could be restored by exposure of the myelin basic protein (MBP)-reactive T cells to IL-12 with the subsequent induction of the ability to transfer EAE to naive recipients. These findings have important implications for the therapeutic use oflL-12 and IL-12 antagonists and may explain the association between relapses/exacerbation ofautoimmune disease and infectious diseases.
E
AE is a demyelinating disease of the central nervous system induced by an autoimmune response against myelin proteins, particularly myelin basic protein (MBP) and its derivative peptides (1) (2) (3) . EAE is mediated by CD4+ T cells and the T cells responsible for disease induction produce Thl type cytokines. Thus, MBP-reactive T cell clones and lines that are encephalitogenic have been found to produce either IFN% TNFoL, or TNF[~ or a combination of these cytokines, while T cell clones or lines that produce IL-4 or IL-10 are non-encephalitogenic (4) (5) (6) (7) (8) . Exposure of MBP-reactive LN cells to IL-12, a powerful inducer of IFN',/, enhances their encephalitogenicity. Conversely, treatment of animals that have received MBP-reactive cells with neutralizing antibodies to IL-12 attenuates the symptomatology of EAE (9) . Examination of spinal cords from diseased animals has revealed the presence of mRNA for IFN"/and TNF during clinical episodes, whereas mRNA for IL-10 appeared at the time of clinical remissions (10) . This suggests that remissions may be induced by downregulation of the Thl response by the production of Th2-type cytokines. Furthermore, EAE can be ameliorated by the infusion of either IL-4 or IL- 10 (11-12) .
Inbred strains of mice exhibit a spectrum of susceptibility to induction of EAE. The MHC plays a critical role in disease susceptibility and strains bearing H2 s or H2 u haplotypes have been found to be susceptible, while those bearing H2 a or H2 k are resistant. One important exception is the B10.S strain, which is resistant to both active and passive EAE despite bearing the same MHC (H2 9 as mice of the prototypical susceptible strain, SJL (13) . In this paper, we compare the immune responses of the SJL and B10.S strains to MBP in an attempt to uncover factors that may control resistance/susceptibility to EAE. As the differential induction of a Thl vs a Th2 response has been shown to critically influence both the immune responses of different mouse strains to infection by pathogens and the immune responses needed for induction of autoimmune diseases (14-16), we have focused our efforts on a comparison of cytokine production by the two strains. We demonstrate that the resistance of the B10.S strain to the induction of EAE after immunization with MBP is secondary to an antigen-specific defect in the generation of Thl cells that produce IFN',/. However, the defect in IFN~ production can be corrected by exposure of the MBP-reactive T cells to IL-12 in vitro with the subsequent induction of encephalitogenic T cells. These results have important implications for furthering our understanding of the role of cytokines in the susceptibility to, and pathogenesis of, autoimmune disease.
Materials and Methods
Mice. Female B10.S and SjL/j mice were obtained from McLaughlin Research Institute (Great Falls, MT) and Jackson Laboratory (Bar Harbor, ME), respectively, and kept in a pathogen free facility. All mice were 8-12 wk of age when experiments were initiated.
Antigens. MBP was prepared from guinea pig spinal cords, as previously described (17) , Peptides corresponding to residues 260-283 of Influenza A nucleoprotein (NP260_28> ARSALIL-RGSVAHKSCLPACVYGP), and residues 87-106 of MBP (MBPs:_m6, VVHFFKNIVTPRTPPPSQGK) were synthesized and purified by HPLC by the Laboratory of Molecular Structure, Peptide Synthesis Laboratory (NIAID, NIH, Bethesda, MD).
Immunization. Mice were immunized subcutaneously at four sites over the flanks with an emulsion containing equal volumes ofCFA (DIFCO Laboratories, Detroit, MI) and antigen dissolved in PBS. Each mouse received a total of 0.1 ml of emulsion (0.025 ml/site) containing 30 lag of Mycobacterium tuberculosis and an optimal dose of the relevant antigen. Optimal doses were determined in pilot experiments as follows: MBP, 400 lag; NP2~0_283, 5 txg; MBP87_I06, 100 lag.
Generation qf Ag-Spec!fic LN Cells for Cell Transfer and Analysis of
Cytokine Production. 10-11 d after immunization draining LN cells (inguinal and axillary) were removed and processed as previously described. Cells were cultured in RPMI 1640 containing 10% FCS and standard supplements (18) with either MBP (25 lag/ml), MBP87_10(, (50 ~g/ml), or NP260_2s 3 (12.5 lag/ml). Supernatants were removed at 24 h intervals for quantification of cytokine levels. After four days of culture, cells were harvested and washed extensively. Some of these cells were injected into naive recipients (35 X 106 cells/mouse intraperitoneal) to test their encephalitogenicity. Other cells were recultured in fresh medium with or without soluble antigen and supernatants were removed at 24 and 48 h for cytokine analysis.
Where specified, cytokines or neutralizing antibodies were added to the primary cultures as follows: IL-12, 20 ng/ml (gift of S. Wolf, Genetics Institute, Cambridge, MA); anti-IL-4 mAb, 10 btg/ml (clone 11Bll; gift of W.E. Paul, NIAID, NIH); rat antimouse IL-10 mAb, 0.5 lag/ml (clone JES5-2A5; PharMingen, San Diego, CA); recombinant murine IFN',/, 30 ng/ml (Pharmingen); and anti-mouse IFNT, 20 lacg/ml (clone XMG 1.2; gift ofR. Seder, NIAID, NIH).
Pur!fication of T Cells. T cells were purified to levels of'-'90%
purity from LN cell preparations by passage through nylon wool columns followed by "mouse T cell enrichment" columns (R & D Systems, Minneapolis, MN). Recovered T cells were washed twice, resuspended in complete medium at 1 X 106 cells/well, and then cocultured with irradiated (3,000 rads) splenocytes added at a 1:4 ratio. Before being added, splenocytes were de- Cytokine ELISA. Cytokines were quantified using a sandwich ELISA technique based on noncompeting pairs of antibodies. The capture and detection mAbs used for each cytokine were obtained from PharMingen except for rabbit anti-mouse IFNy (Spring Valley Laboratories, Woodbine, MD). Goat anti-rabbit lgG-HRP (Southern Biotechnology Associates, Inc., Birmingham, AL) was used as a tertiary Ab in the IFN'y ELISA. Peroxidase labeled streptavidin (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) was applied as a last step in the ELISAs using biotinylated detection antibodies. Plates were developed with TMB peroxidase substrate (Kirkegaard & Perry) and stopped with 10% sulfuric acid.
Clinical Evaluation. After injection of MBP-reactive cells, mice were examined daily for signs ofneurologic impairment and rated for severity of symptomatology as previously described (18) . (Fig. 1 A) and produced comparable quantities of IL-2 in an antigen-specific manner (data not shown). However, LN cells from SJL mice produced significant quantities of IFN'y which accumulated over time, while LN cells from B10.S mice failed to secrete detectable quantities of that cytokine (Fig.  1 B) . Furthermore, LN cells from B10.S mice failed to produce significant amounts of IFNy upon secondary in vitro stimulation, while LN cells from SJL produced heightened amounts of IFNy with accelerated kinetics (Fig. 1 C) . TNFcl production was not detectable in LN cells of either strain (data not shown). The failure of the B10.S mice to produce 1FN'y was not related to the overproduction of suppressive Th2 cytokines as LN cells from neither strain produced detectable amounts oflL-4 or IL-10 (data not shown), nor did the addition of anti-IL-4 or anti-IL-10 alone or in combination to primary cultures restore the capacity of B10.S T cells to produce IFN'y on secondary in vitro stimulation with MBP (see Fig. 3 ). Furthermore, treatment of B10.S animals during the course of priming with MBP with large quantities of a neutralizing anti-IL-4 mAb (0.5 mg of 11B1 1 intraperitoneal on day 0, 3, and 7) failed to result in IFN~ production upon stimulation of the LNC in vitro (data not shown). The defect was also not related to a failure of pro- cessing or presentation of the encephalitogenic epitope of MBP as similar results were obtained after immunization of the two strains with the encephalitogenic peptide, MBP87_t06 (Fig. 1 D) . In addition, the inability ofMBP-reactive B10.S T cells to produce IFN'y was not secondary to a defect in cytokine production by B10.S APC. The capacity of purified MBP-specific B10.S T cells to produce IFN~/was not restored when they were cultured with T-depleted spleen cells from SJL mice, nor was the capacity of MBP-specific SJL T cells to produce IFN~/ diminished when they were cultured with B10.S T-depleted spleen cells (data not shown). Although the studies shown above were performed with unseparated LNC or purified T cells, identical results were observed when highly purified CD4+ T cells were stimulated with MBP in the presence of T-depleted spleen cells from normal animals. The inability of B10.S LNC to produce IFN~/ in response to MBP was antigen-specific as primed B10.S LNCs produced significant quantities of IFN~/ on both primary and secondary in vitro stimulation with a peptide of Influenza A virus nucleoprotein, NP260_283, previously shown to be highly immunogenic in this strain (19) (Fig. 2, A and B) . Primed B10.S LNC also produced as much IFN'y as primed SJL LNC when stimulated in vitro with PPD (data not shown).
Results

BIO.S Mice Have A Specific Defect in IFNT Production in
Reconstitution of the Capacity of MBP-primed BIO.S LNCs to Produce IFNy by Treatment with IL-12. As IL-12 has been
shown to play a critical role in the induction of IFN~/production in response to several pathogens, we attempted to induce IFN~/production by MBP-primed B10.S T cells by adding IL-12 to the primary in vitro cultures. Surprisingly, the addition of IL-12 resulted in substantial production of IFN~/in the secondary cultures that was equal to or greater than that produced by LN cells from SJL mice on secondary in vitro challenge. The presence of neutralizing mAb to IFN~/did not compromise the ability of IL-12 to promote IFN~/production on subsequent challenge, suggesting that the effect of IL-12 is direct and not mediated by the IFN'y it induces. Furthermore, the addition of IFN~/ to the pri-
Primary Culture
Secondary Culture mary cultures failed to prime for its own synthesis (Fig. 3) . No enhancement of IFN~/ production in secondary cultures was seen when either anti-IL-4 or anti-IL-10 were used together with IL-12 in the primary cultures (Fig. 3) .
Encephalitogenicity of IL-12-treated BIO.S and SJL LNC.
The capacity of LN cells from MBP-primed mice to transfer EAE to normal adoptive recipients is dependent on restimulation of the cells in culture. However, the critical parameters that permit in vitro stimulated cells to induce disease have not been fully elucidated. Although the induction of IFN-/ production by MBP-specific B10.S T cells with IL-12 is of interest, it is not clear if the production of IFN~/per se relates to the capacity ofMBP-specific effector cells to induce EAE in vivo. We therefore transferred SJL and B10.S T cells that had been cultured with MBP alone or B10.S T cells which had been cultured with MBP in the presence of IL-12 to naive recipients and monitored them for the induction of EAE. MBP-reactive cells from SJL mice transferred moderate to severe relapsing-remitting EAE with 100% incidence, while no disease was observed in recipients ofMBP-reactive T cells from B10.S mice during a 40 d follow-up period. More importantly, B10.S T cells that had been cultured with MBP and IL-12 acquired the ability to induce EAE upon adoptive transfer. The resultant disease occurred at 100% incidence, but was not as severe as that induced by SJL LNC. The induction of EAE was absolutely dependent on the presence of MBP-specific T cells as B10.S LNCs sensitized to NP260_283 and exposed to IL-12 do not induce EAE (Table 1) .
Discussion
Multiple genetic factors control the susceptibility of experimental animals and man to autoimmune diseases. Although the MHC plays a major role in determining the susceptibility of rodents to EAE, our comparison of the factors responsible for the induction of EAE in the B10.S and SJL strains which both bear H-2 ~ has defined a critical, non-MHC related, step in the activation cascade of autoreactive T cells that is defective in the B10.S mouse. We initially reasoned that resistance of B10.S mouse to MBPinduced EAE was mediated at the level of the T cell and APC and was not due to factors peripheral to the immune reaction, such as the impermeability of the blood-brain barrier or resilience of the oligodendrocyte to autoimmune attack, as B10.PL (H-2 ~) mice are readily susceptible to induction of EAE (4, 20) . Hence, there is no characteristic of the B10 background which prevents manifestations of EAE if functional encephalitogenic T cells are present and properly primed. We found that the distinguishing characteristic of the B10.S immune response to intact MBP, as well as to MBP87q06, was the failure of primed T cells to produce IFNy in vitro in the presence of a vigorous IL-2-driven antigen-specific proliferative response. This failure to produce IFNy in response to MBP was antigen-specific and was not secondary to an ongoing Th2 response.
MBP-reactive B10.S LN cells acquired the ability to produce IFNy upon exposure to IL-12 during primary ex vivo challenge with antigen. Furthermore, this ability was retained upon subsequent antigenic challenge in the absence of IL-12. Concomitantly, exposure to IL-12 unmasked the latent potential of these T cells to induce EAE on adoptive transfer. It is not clear whether the acquisition of the capacity to produce IFNy was directly responsible for encephalitogenicity of the IL-12-treated T cells. It is possible that IL-12 has an effect on T cells in addition to its well characterized ability to prime for IFNy production that is critical in conferring encephalitogenicity. Indeed, previous studies have raised the possibility that endogenous IL-12 might play a role in the pathogenesis of EAE by inducing the upregulation of adhesion molecules (9) . The role ofIFN~/in the pathogenesis of EAE is not well understood as attempts to assess the effect of neutralizing antibodies to IFN',/ on the disease have yielded contradictory results (21-23) and mice of a susceptible strain with a disrupted IFN~ gene still manifest clinical signs of EAE after transfer of MBP-reactive cells (24) . Hence, although IFNy might play an integral role in establishing or perpetuating the CNS inflammation characteristic of EAE, its presence is not essential and probably can be compensated by production of other proinflammatory cytokines. The induction of IFN'y production by IL-12 may thus simply serve as a surrogate marker of encephalitogenicity. We cannot as yet conclude that reconstitution ofencephalitogenicity by treatment of primed B10.S T cells with IL-12 is indicative of a critical role for this cytokine in the induction of IFNy production in vivo as studies with neutralizing anti-IL-12 reagents in vivo are still in progress.
In conclusion, we have found that exposure to IL-12 unmasks a latent capacity of MBP-reactive T cells from a resistant strain to transfer EAE. These findings have important imphcations for the use oflL-12 or antagonists to IL-12 for therapeutic purposes. Use of IL-12 as an adjunct in anti-tumor therapy or as a component of a vaccine could trigger an autoimmune syndrome in genetically predisposed individuals. Our results also suggest that the association between intercurrent infections and presentation or relapse ofautoimmune diseases, including multiple sclerosis (25, 26) , may he secondary to IL-12 production in response to pathogens. On the other hand, our data support the view that antagonists to IL-12 may have therapeutic value in the treatment of inflammatory autoimmune diseases by inhibiting the activation and/or action ofThl T cells.
